Deepak Nitrite Ltd (DEEPAKNTR) Q1 FY27 Earnings Call: EBITDA Margin Expands to 21%, Capex Pipeline at Rs. 11,500 Cr

Deepak Nitrite Ltd held its Q1 FY27 earnings call on August 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Revenue, Margin Expansion, and Profit Surge

• Consolidated revenue of Rs.2,592 Cr — up 35% YoY and 22% QoQ, driven by record performance in both Phenolics and Advanced Intermediates segments.
• EBITDA of Rs.554 Cr (record) — up 169% YoY and 45% QoQ; margin expanded to 21% from 11% in Q1 FY 2025-2026, supported by asset utilization, backward integration, and manufacturing efficiencies.
• PAT of Rs.345 Cr — up 207% YoY and 57% QoQ; PBT hit a record Rs.468 Cr, up 202% YoY.
• Phenolics segment revenue of Rs.1,775 Cr — highest ever, up 36% YoY and 24% QoQ; EBIT margin of 24%.
• Advanced Intermediates revenue of Rs.804 Cr — up 33% YoY and 14% QoQ; EBIT margin of 8% (EBIT up 89% YoY and 100% QoQ).
• Domestic-to-export mix of 85:15 — exports grew healthily; consolidated net worth at Rs.6,214 Cr; debt-to-equity ratio of 0.27x.

Debottlenecking, New Plants, and Polycarbonate Timeline

• Phenol plant achieved 400,000 tons annualized run rate — in Q1 FY 2026-2027, with some periods of lower output due to raw material sourcing and scheduled maintenance; management targets debottlenecking to reach 400 KTPA capacity in the short to medium term.
• MIBK and MIBC exceeded designed capacity — pre-commissioning runs met stringent consumption norms; customer approval received; management expects to ramp to beyond 100% utilization quickly once demand materializes.
• Acetophenone commissioning in August 2026 — integrated model expected to deliver the lowest product carbon footprint globally, with top quality and low PCS scores; capacity figure not disclosed.
• Alkylation and multipurpose plants delayed — commercial volumes now expected from January 2027 (within FY 2026-2027) due to contractual manpower shortages and natural gas disruption in Q1.
• Polycarbonate project on track — commissioning targeted for H2 FY 2028-2029, with BPA expected a few months after; seed marketing qualified with marquee customers; India remains entirely import-dependent for polycarbonate.
• Government reimposed import duty on phenol — management noted "the government reimposed the import duty on phenol after removing it temporarily during Q1 FY26-27", supporting domestic pricing dynamics.
• New 300 KTPA phenol plant at Deepak Chemtech — will serve as integration platform for downstream BPA, polycarbonate, and compounding; phenol capacity timed to align with PDH-based propylene supply.

Volume Uptick, Export Mix, and Supply Chain Mitigation

• AI segment revenue of Rs.804 Cr — up 33% YoY and 14% QoQ; export/domestic mix within AI is approximately 40-50% export by value, varying quarter-on-quarter.
• Consolidated business mix ~80% domestic, 20% export — phenolics segment is almost entirely domestic; a significant portion of export business is negotiated with key innovators based in Japan or Europe.
• No incremental inventory benefit in Q1 FY 2026-2027 — management confirmed disciplined inventory management with no one-time boost; feedstock was secured successfully amid volatile conditions.
• "Uptick in terms of volume demand" — management observed demand acceleration across all verticals and businesses in Q1 FY 2026-2027.
• Export strategy adapting to supply chain disruptions — management is changing product composition to alter hazardous classification (e.g., sodium nitrite), shifting from CIF to FOB models, and consolidating volumes into bulk parcels to reduce per-kilo freight costs.
• Amines integration complete — management stated the company is now "a nitrogen company that nitrates" rather than a nitration company buying nitric acid; capabilities span amination, diazotization, and fluorination.

Flow Chemistry Breakthroughs and Competitive Dynamics

• Flow chemistry reduces reaction time from 16-18 hours to 45-52 seconds — management provided an example of a product currently produced in batch; the platform focuses on NOx chemistry and enables multi-product campaigns with rapid changeover.
• Commercial-scale flow chemistry deployment in FY 2027-2028 — current focus in Q1 FY 2026-2027 is on gaining market traction with seed samples; the platform allows exploitation of a few chemistries to make 20 different products.
• R&D investments not yet reflected in gross margins — management acknowledged intense competition in nitration and diazotization platforms ("red ocean" environment) has limited margin expansion despite R&D progress.
• New Chinese regulations on dangerous chemistries — management cited "new Chinese regulations prohibiting 'casual investment' in new capacities for inherently dangerous chemistries" as a factor expected to improve the competitive landscape.
• Customer validation cycles of 2-12 months — optical brighteners validation for detergent majors took over 24 months; new molecules from the R&D pipeline are expected to have better margin profiles as competition intensity eases.
• R&D shifting to cross-functional teams — combining organic chemists, physical chemists, and chemical engineers to address flow chemistry challenges at lab and industrial scales.

Rs.11,500 Cr Project Spend, Debt Profile, and Funding

• Total capex plan of Rs.11,500 Cr — cumulative spend of Rs.1,200 Cr as of Q1 FY 2026-2027; additional Rs.1,000-Rs.1,500 Cr planned in FY 2026-2027, bringing cumulative to ~Rs.3,200 Cr by end of FY 2026-2027.
• FY 2026-2027 capex guided at ~Rs.3,500 Cr — Rs.1,200 Cr already spent; further Rs.1,500-Rs.1,600 Cr planned for the remainder of the year; FY 2027-2028 capex of ~Rs.3,000 Cr planned, bringing total project spend to ~Rs.6,000 Cr over the two years.
• Current borrowings of Rs.6,800 Cr — against total assets of Rs.11,500 Cr as of Q1 FY 2026-2027; CFO Sanjay Upadhyay reported peak debt expected at Rs.8,000-Rs.8,500 Cr by FY 2028-2029, with debt-to-equity ratio not exceeding 1.
• Funding secured at competitive rates — 25% equity already contributed; bank debt tie-up completed for the balance; debt-to-equity ratio of 0.27x as of Q1; project funded at 60:40 debt-to-equity.
• Capex directed toward long-lead items — including assets sourced from outside India and set up locally; no significant working capital shift expected for specialized sectors post polycarbonate commercialization.
• Strategic partnerships for polycarbonate compounds under NDA — management declined to comment on aerospace applications or specific gross margins, but stated the project has a "formidable IRR".

Commissioning Cadence, Margin Outlook, and Risks

• MIBK, MIBC, and acetophenone commissioning in August 2026 — within Q2 FY 2026-2027; multipurpose agrochemical intermediates facility also expected within Q2; rest of the multipurpose facility within Q2 as well.
• Alkylation and multipurpose plants: commercial volumes from January 2027 — delayed from Q1 due to contractual manpower shortages and natural gas disruption; new advanced intermediates products expected to have margin profile in line with or better than existing average.
• Polycarbonate commissioning in H2 FY 2028-2029 — BPA expected a few months after; phenol capacity at Chemtech timed to align with PDH-based propylene supply; technology supplier will be an anchor customer.
• Management confident in sustaining earnings momentum — despite geopolitical and pricing volatility risks; improved asset utilization, backward integration, and manufacturing efficiencies cited as key margin drivers.
• Renewable energy transition underway — expected to improve both sustainability and cost competitiveness over time.
• Risks: global commodity pricing volatility, geopolitical disruptions, and competitive intensity in nitration/diazotization platforms remain headwinds; customer validation cycles for new products can extend to 12-24 months.